CCL

Összesen 8 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM125172
035-os BibID:(scopus)85207507392 (WOS)001341961400001
Első szerző:Berta Eszter (belgyógyász)
Cím:Low Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto's Thyroiditis on Levothyroxine Substitution / Berta Eszter, Halmi Sándor, Molnár István, Hutkai Dávid, Csiha Sára, Bhattoa Harjit Pal, Lőrincz Hajnalka, Somodi Sándor, Katkó Mónika, Harangi Mariann, Paragh György, Nagy Endre V., Bodor Miklós
Dátum:2024
ISSN:2218-1989
Megjegyzések:Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto's thyroiditis (HT). Methods: Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay. Results: Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4?148.3) pg/mL vs. 131.9 (44.8?236.3) pg/mL; p = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy. Conclusions: Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
thyroid
fibroblast growth factor 21
FGF21
Hashimoto's thyroiditis
levothyroxine
hyperlipidemia
hypothyroidism
Megjelenés:Metabolites. - 14 : 10 (2024), p. 1-10. -
További szerzők:Halmi Sándor (1986-) (belgyógyász) Molnár István (1991-) (belgyógyász) Hutkai Dávid (1990-) (belgyógyász, nefrológus) Csiha Sára (1985-) (Biológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Lőrincz Hajnalka (1986-) (biológus) Somodi Sándor (1977-) (belgyógyász) Katkó Mónika (1980-) (biológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Paragh György (1953-) (belgyógyász) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Bodor Miklós (1969-) (belgyógyász, endokrinológus)
Pályázati támogatás:K142273
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM127743
035-os BibID:(WoS)001430570300001 (Scopus)85218879981
Első szerző:Csiha Sára (Biológus)
Cím:Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy / Sára Csiha, Marcell Hernyák, Ágnes Molnár, Hajnalka Lőrincz, Mónika Katkó, György Paragh, Miklós Bodor, Mariann Harangi, Ferenc Sztanek, Eszter Berta
Dátum:2025
ISSN:2227-9059
Megjegyzések:Background/Objectives: Type 2 diabetes mellitus (T2DM) and its macro- and microvascular complications are major health concerns with multiple factors, like advanced end glycation products (AGEs), in the background. AGEs induce long-lasting functional modification of the proteins and collagen in the vascular wall and nerve tissue. We investigated the effect of alpha-lipoic acid (ALA) treatment on AGEs, soluble AGE receptor (sRAGE), the AGE/sRAGE ratio, and the parameters of endothelial dysfunction and their correlations. Methods: In our 6-month intervention study, 54 T2DM patients with neuropathy treated according to the actual therapeutic guidelines with unchanged oral antidiabetic drugs were included and treated by daily oral administration of 600 mg ALA. A total of 24 gender and age-matched T2DM patients without neuropathy served as controls. Results: In our work, we first demonstrated the attenuating effect of alpha lipoic acid therapy on AGEs in humans (11.89 (9.44?12.88) to 10.95 (9.81?12.82) AU/?g (p = 0.017)). sRAGE levels or the AGEs/sRAGE ratio were not affected by ALA treatment or by the presence of neuropathy. We found a correlation between the changes of AGEs and the improvement of current perception threshold and progranulin levels, and an inverse correlation with the change of asymmetric dimethylarginine. Conclusions: According to our results, ALA decreases AGEs, which may contribute to the clinically well-known beneficial effect in diabetic neuropathy and improvement of endothelial function.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
advanced glycation end products
AGEs
sRAGE
diabetic neuropathy
alpha lipoic acid
atherosclerosis
oxidative stress
ADMA
progranulin
Megjelenés:Biomedicines. - 13 : 2 (2025), p. 1-16. -
További szerzők:Hernyák Marcell (1981-) (orvos) Molnár Ágnes (1972-) (gyógytornász) Lőrincz Hajnalka (1986-) (biológus) Katkó Mónika (1980-) (biológus) Paragh György (1953-) (belgyógyász) Bodor Miklós (1969-) (belgyógyász, endokrinológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Sztanek Ferenc (1982-) (orvos) Berta Eszter (1980-) (belgyógyász)
Pályázati támogatás:K142273
OTKA
EKÖP-24-3-II-DE-303
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM112354
035-os BibID:(WoS)001003354300001 (Scopus)85161358752
Első szerző:Csiha Sára (Biológus)
Cím:Advanced glycation end products and their soluble receptor (sRAGE) in patients with Hashimoto's thyroiditis on levothyroxine substitution / Sára Csiha, István Molnár, Sándor Halmi, Dávid Hutkai, Hajnalka Lőrincz, Sándor Somodi, Mónika Katkó, Mariann Harangi, György Paragh, Endre V. Nagy, Eszter Berta, Miklós Bodor
Dátum:2023
ISSN:1664-2392
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Frontiers in Endocrinology. - 14 (2023), p. 1-9. -
További szerzők:Molnár István (1991-) (belgyógyász) Halmi Sándor (1986-) (belgyógyász) Hutkai Dávid (1990-) (belgyógyász, nefrológus) Lőrincz Hajnalka (1986-) (biológus) Somodi Sándor (1977-) (belgyógyász) Katkó Mónika (1980-) (biológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Paragh György (1953-) (belgyógyász) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Berta Eszter (1980-) (belgyógyász) Bodor Miklós (1969-) (belgyógyász, endokrinológus)
Pályázati támogatás:K142273
OTKA
ÚNKP-21-4.2
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM105694
Első szerző:Csiha Sára (Biológus)
Cím:Association of chemerin and serum advanced glycation end products in patients with autoimmune thyroiditis / Bak-Csiha Sara, Halmi Sandor, Hutkai David, Molnar Istvan, Katko Monika, Lőrincz Hajnalka, Harangi Mariann, Paragh Gyorgy, Nagy Endre, Bodor Miklos, Berta Eszter
Dátum:2022
ISSN:1479-6848
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
folyóiratcikk
Megjelenés:Endocrine Abstracts. - 81 (2022), p. EP400. -
További szerzők:Halmi Sándor (1986-) (belgyógyász) Hutkai Dávid (1990-) (belgyógyász, nefrológus) Molnár István (1991-) (belgyógyász) Katkó Mónika (1980-) (biológus) Lőrincz Hajnalka (1986-) (biológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Paragh György (1953-) (belgyógyász) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Bodor Miklós (1969-) (belgyógyász, endokrinológus) Berta Eszter (1980-) (belgyógyász)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM106172
035-os BibID:(scopus)85145670780 (wos)000909053600001
Első szerző:Galgóczi Erika (biológus)
Cím:Glucocorticoids Directly Affect Hyaluronan Production of Orbital Fibroblasts : a Potential Pleiotropic Effect in Graves' Orbitopathy / Galgoczi Erika, Katko Monika, Papp Fruzsina Reka, Csiki Robert, Csiha Sara, Erdei Annamaria, Bodor Miklos, Ujhelyi Bernadett, Steiber Zita, Gyory Ferenc, Nagy Endre V.
Dátum:2022
ISSN:1420-3049
Megjegyzések:Orbital connective tissue expansion is a hallmark of Graves' orbitopathy (GO). In moderateto-severe active GO, glucocorticoids (GC) are the first line of treatment. Here we show that hydrocortisone (HC), prednisolone (P), methylprednisolone (MP), and dexamethasone (DEX) inhibit the hyaluronan (HA) production of orbital (OF) and dermal (DF) fibroblasts. HA production of GO OFs (n = 4), NON-GO OFs (n = 4) and DFs (n = 4) was measured by ELISA. mRNA expression of enzymes of HA metabolism and fibroblast proliferation was examined by RT-PCR and BrdU incorporation, respectively. After 24 h of GC treatment (1?M) HA production decreased by an average of 67.9 ? 3.11% (p < 0.0001) in all cell cultures. HAS2, HAS3 and HYAL1 expression in OFs also decreased (p = 0.009, p = 0.0005 and p = 0.015, respectively). Ten ng/mL PDGF-BB increased HA production and fibroblast proliferation in all cell lines (p < 0.0001); GC treatment remained effective and reduced HA production under PDGF-BB-stimulated conditions (p < 0.0001). MP and DEX reduced (p < 0.001, p = 0.002, respectively) PDGF-BB-induced HAS2 expression in OFs. MP and DEX treatment decreased PDGF-BB stimulated HAS3 expression (p = 0.035 and p = 0.029, respectively). None of the GCs tested reduced the PDGF-BB stimulated proliferation rate. Our results confirm that GCs directly reduce the HA production of OFs, which may contribute to the beneficial effect of GCs in GO.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Graves' orbitopathy
hyaluronan
glucocorticoids
hyaluronan synthase
methylprednisolone
prednisolone
hydrocortisone
dexamethasone
Megjelenés:Molecules. - 28 : 1 (2022), p. 1-12. -
További szerzők:Katkó Mónika (1980-) (biológus) Papp Fruzsina Réka (1995-) (klinikai laboratóriumi kutató) Csiki Róbert (1997-) (gyógyszerész) Csiha Sára (1985-) (Biológus) Erdei Annamária (1976-) (belgyógyász) Bodor Miklós (1969-) (belgyógyász, endokrinológus) Ujhelyi Bernadett (1981-) (szemész) Steiber Zita (1977-) (orvos, szemész) Győry Ferenc (1964-) (sebész) Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Pályázati támogatás:OTKA-K143464
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM103912
Első szerző:Lengyel Inez (belgyógyász)
Cím:Characterization of fetuin-A levels in patients with autoimmune thyroid disease / Lengyel I., Halmi S., Lőrincz H., Bak-Csiha S., Katkó M., Harangi M., Nagy E. V., Paragh G., Bodor M., Berta E.
Dátum:2022
ISSN:0021-9150
Megjegyzések:Background and Aims : Hypothyroidism leads to atherogenic lipid profile and might increase the cardiovascular risk of patients. Fetuin-A is a hepatokine with a regulatory role on mineralization, metabolism and the cardiovascular system. Fetuin-A is increased in obesity-linked diseases Methods: In our study we investigated the association between thyroid hormone levels, the components of lipid metabolism, anthropometrical parameters and fetuin-A. We enrolled eighty-six patients (7 men, 79 women, mean age 43?13 years, median BMI 25.3 (23.4-30.5) kg/m2) from the Endocrine outpatient clinic of the Department of Medicine, Debrecen. Our patients had autoimmune thyroid disease; their thyroid hormone status varied from hypo- to hyperthyroidism. Serum fetuin-A concentrations were determined with enzyme-linked immunosorbent assay (ELISA). Thyroid hormone levels and lipid parameters were measured by routine laboratory methods. Results: Median serum fetuin-A level was 929.7 (822.0 ? 1038.3) mg/L, LDL-C was 3.2 (2.6-3.8) mmol/l, HDL-C was 1.5 (1.3-1.8), triglyceride was 0.84 (0.49-1.45) mmol/l, while mean total cholesterol level was 5.3?1.1 mmol/l. Mean fT3 and fT4 were 4.67?0.67 and 17.8?3.6 pmol/l, respectively. Significant positive correlation was found between fT3 and fetuin-A levels. There was a significant negative correlation between ApoB100, total cholesterol and fT3. Significant negative correlation was found between TSH and log triglyceride. Among patients receiving levothyroxine substitution, a correlation between CRP and fT3 was present. Conclusions: The significant correlation between fetuin-A and fT3 levels might indicate a regulatory effect of fT3 on metabolism. However, further clinical investigations are needed to clarify the effect of thyroid status on hepatokine levels.
Tárgyszavak:Orvostudományok Egészségtudományok idézhető absztrakt
folyóiratcikk
autoimmune thyroid disease
fetuin-A
hepatokine
Hypothyroidism
atherosclerosis
lipid metabolism
Megjelenés:Atherosclerosis. - 355 (2022), p. e247-e248. -
További szerzők:Halmi Sándor (1986-) (belgyógyász) Lőrincz Hajnalka (1986-) (biológus) Csiha Sára (1985-) (Biológus) Katkó Mónika (1980-) (biológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Paragh György (1953-) (belgyógyász) Bodor Miklós (1969-) (belgyógyász, endokrinológus) Berta Eszter (1980-) (belgyógyász)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM133290
Első szerző:Ratku Balázs (mentőtiszt)
Cím:Alterations of lipoprotein subfractions in GH-deficient adults / Balázs Ratku, Hajnalka Lőrincz, Sára Csiha, Lajos Bíró, Annamária Erdei, Eszter Berta, Dóra Ujvárosy, Miklós Bodor, Endre V. Nagy, Zoltán Szabó, Mariann Harangi, Sándor Somodi
Dátum:2025
ISSN:1664-2392
Megjegyzések:Introduction: Dyslipidemia is a common complication of adult growth hormone de ciency (AGHD) and considered an important contributor to increased mortality. Previous studies mainly focused on quantitative assessment of lipoproteins, but lipoprotein subfractions and their relationship with insulin-like growth factor 1 (IGF-1) have not been explored. Purpose: To perform a comprehensive evaluation of lipoprotein subfractions and measuring apolipoprotein L1 (apoL1), sphingosine 1-phosphate (S1P) and apolipoprotein M (apoM) in AGHD. Materials and methods: 11 GH-substituted (GHS) patients, 9 GH-unsubstituted (GHU) patients and 37 controls were included in the study. Lipoprotein subfractions were separated by the Lipoprint system. ApoL1, apoM and S1P were determined by ELISA. In the GHS patients GH-replacement was discontinued for 2 months. Measurements were performed before GH- discontinuation, at the end of the 2-month GH-withdrawal, and 1 month after reinstituting GH-replacement. Results: Standard lipid parameters, apoM and apoL levels were not different between the groups. GHU patients demonstrated lower apolipoprotein A1 compared to controls (p=0.02) and higher apolipoprotein B100 compared to GHS (p=0.02). GHU and GHS showed higher S1P levels compared to controls (p=0.04 and p=0.01, respectively). Both GHU and GHS patients also presented higher percentage of intermediate-density lipoprotein (IDL) compared to controls (p=0.03 and p=0.01, respectively). Mean LDL size was lower in GHU compared to GHS (p=0.04). Percentage of intermediate HDL was lower in GHU and GHS compared to controls (p<0.001 and p<0.01, respectively). GHU demonstrated higher percentage of small HDL than controls (p<0.001). Overall, log10IGF-1 correlated positively with the percentage of large HDL (r=0.27; p=0.04) and intermediate HDL (r=0.38; p<0.01) and negatively with the percentage of small HDL (r=-0.46; p<0.01). Log10IGF-1 was the best predictor of small HDL (standardized b=-0.46; p<0.001) in overall subjects. In the GH-withdrawal study, the amount of HDL-6 increased with GH-withdrawal (p=0.03) and the percentage of IDL increased with reinstitution (p=0.05). Conclusion: Despite no changes in standard lipid parameters, considerable alterations of lipoprotein subfractions were revealed in GH-de cient adults indicating that lipoprotein subfraction analysis may allow for a more precise cardiovascular risk assessment in AGHD. Associations between HDL subfractions and Log10IGF-1 demonstrate a novel insight into the role of GH in lipid metabolism.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
adult growth hormone de ciency
dyslipidemia
high-density lipoprotein
ipoprotein subfractions
sphingosine 1-phosphate
insulin-like growth factor 1
Megjelenés:Frontiers in Endocrinology. - 16 (2025), p. 1-14. -
További szerzők:Lőrincz Hajnalka (1986-) (biológus) Csiha Sára (1985-) (Biológus) Biró Lajos Erdei Annamária (1976-) (belgyógyász) Berta Eszter (1980-) (belgyógyász) Ujvárosy Dóra (1985-) Bodor Miklós (1969-) (belgyógyász, endokrinológus) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Somodi Sándor (1977-) (belgyógyász)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM118422
035-os BibID:(WoS)001165227400001 (Scopus)85185245598
Első szerző:Ratku Balázs (mentőtiszt)
Cím:Serum afamin and its implications in adult growth hormone deficiency : a prospective GH-withdrawal study / Balázs Ratku, Hajnalka Lőrincz, Sára Csiha, Veronika Sebestyén, Eszter Berta, Miklós Bodor, Endre V. Nagy, Zoltán Szabó, Mariann Harangi, Sándor Somodi
Dátum:2024
ISSN:1664-2392
Megjegyzések:Introduction: Adult growth hormone deficiency (AGHD) is associated with a high prevalence of metabolic syndrome (MS), which contributes to the unfavorable cardiovascular risk profile in these patients. Insulin like growth factor-1 (IGF-1) is a widely used biomarker, however it does not always reflect the cardiometabolic risk and has a poor relationship with clinical efficacy endpoints. Consequently, there is an unmet need for biomarkers to monitor responses to GH-replacement. Afamin is a hormone-like glycoprotein, expressed in the liver. Higher afamin levels are strongly associated with MS and insulin resistance (IR). Although both MS and IR are very common in AGHD, afamin has not been investigated in these patients. Purpose: To investigate afamin as a potential biomarker in patients with AGHD. Materials and methods: Participants included 20 AGHD patients (11 GH-substituted and 9 GH-unsubstituted) and 37 healthy controls. Subjects underwent routine laboratory examinations, anthropometric measurements, body composition analysis using multi-frequency bioelectrical impedance analysis (InBody720) and measurement of serum afamin concentrations. In GH-substituted subjects, GH-substitution was withdrawn for 2 months. Measurements were carried out right before GH-withdrawal, at the end of the 2-month withdrawal period, and 1 month after reinstituting GH-replacement therapy (GHRT). Results: GH-unsubstituted patients demonstrated higher afamin levels compared to controls (p=0.03). Afamin positively correlated with skeletal muscle mass, bone mineral content, total body water, extracellular- and intracellular water content, insulin (all, p<0.01), HOMA-IR (p=0.01) and C-peptide (p=0.03) levels in AGHD but not in healthy controls. In GH-substituted patients 2-month of GH-withdrawal caused significant changes in body composition, including decreased fat-free mass, skeletal muscle mass, total body water, and intracellular water content (all, p<0.01); but these changes almost fully recovered 1 month after reinstituting GHRT. Unexpectedly, afamin levels decreased after GH-withdrawal (p=0.03) and increased with reinstitution (p<0.01). Changes of afamin levels during GH-withdrawal positively correlated with changes of HOMA-IR (r=0.80; p<0.01) and changes of insulin (r=0.71; p=0.02). Conclusion: Higher afamin levels in unsubstituted AGHD patients might indicate severe metabolic dysregulation. Significant changes accompanying GH-withdrawal and reinstitution, along with strong correlations with measures of IR, suggest that afamin could be a promising biomarker to monitor GHRT-associated changes of insulin sensitivity.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
adult growth hormone deficiency
growth hormone withdrawal
afamin
body composition
insulin sensitivity
biomarker
Megjelenés:Frontiers in Endocrinology. - 15 (2024), p. 1-13. -
További szerzők:Lőrincz Hajnalka (1986-) (biológus) Csiha Sára (1985-) (Biológus) Borbásné Sebestyén Veronika (1990-) (biofizikus) Berta Eszter (1980-) (belgyógyász) Bodor Miklós (1969-) (belgyógyász, endokrinológus) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Somodi Sándor (1977-) (belgyógyász)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.